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Abstract: Head and neck cancer (HNC) is the sixth most common cancer worldwide and therefore presents a global public health problem. There are no standard algorithms for the diagnosis and follow-up of the disease, and no effective current treatment approaches
exist. Therefore, the discovery of new biomolecules and the design of new strategies to aid in early diagnosis is necessary, along with
establishing prognostic factors of HNC. In several cancer studies, the upregulation of SET Domain, Bifurcated 1 (SETDB1) has been
reported to be tumor-inducing and to indicate a cancer-invasive prognosis, leading to the modulation of genes associated with different
signaling pathways; however, the literature is sparse regarding the relationship between SETDB1 and HNC. In our study, three HNC
primary cell lines and their corresponding metastatic cell lines were used. The quantitative reverse transcriptase-polymerase chain reaction and western blotting data indicated that the SETDB1 mRNA and protein expression levels were higher in all metastatic cell lines
compared to their primary cell lines (P < 0.05 for all). To investigate the role of SETDB1 in HNC biology, in vitro functional analyses
were carried out using small interference RNA (siRNA) technology, cell viability, scratch wound-healing, and the caspase-3 activity assay of gene expression of SETDB1 to compare primary and metastatic cell lines of HNC. Metastatic cells were more susceptible to this
suppression, which decreased the vitality of cells and their ability of wound-healing and induced level of caspase-3 activity (P < 0.05 for
all). This functional study has shown that SETDB1 plays an important role in head and neck carcinogenesis. Therefore, SETDB1 may be
an attractive therapeutic target molecule and also a potential diagnostic and prognostic biomarker in HNC.
Key words: Head and neck cancer, SETDB1, qRT-PCR, western blot, siRNA, cell viability, scratch wound-healing, caspase-3 activity

1. Introduction
Head and neck cancer (HNC) is one of the most
prevalent and deadly cancers in the world and therefore
is an important health problem. It is composed of cancerrelated structures in the head and neck, including the lips,
mouth, nasal cavity, paranasal sinuses, salivary glands,
oropharynx, nasopharynx, hypopharynx, and larynx
(Jemal et al., 2007). The mortality rate is 0.53, and death is
three times more frequent in men (Pehlivan et al., 2008).
Despite many technological advances, there has been
no significant change in survival; metastasis is still the
main cause of death in HNC patients (Jemal et al., 2007).
In most cases, however, 51% of all HNC patients have a
close metastasis, while only 10.5% had distant metastases
identified. The 5-year survival rate was 51% in patients with
close metastases and 28% in those with distant metastases
(Jemal et al., 2007).
HNC is invasive, aggressive, and characterized by
a poor prognosis. In addition, other current treatment

approaches, such as radiotherapy and chemotherapy,
are inadequate due to their toxic effects and drastic
mechanisms of action, along with traditional surgical
practices that reduce patient quality of life. In addition,
the high recurrence rate of HNC and its metastatic
character, which brings into question the efficacy of
current therapeutic approaches, suggests that alternative
treatment methods are needed. Therefore, the discovery
of biomaterials that can be used for the early diagnosis
and follow-up of HNC and the design of new therapeutic
strategies that explain potential molecular mechanisms are
very important.
As with most cancers, various genetic factors play a role
in the pathology of HNC (Renan et al., 1993). In addition
to genetic changes, epigenetic dysregulation, including
downregulation of tumor suppressor genes, activation of
oncogenes and growth factors, and/or expression changes
in target genes in signal pathways, play a key role in HNC’s
pathogenesis (Castilho et al., 2017). However, some recent
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studies have shown that dysregulation of DNA methylation
via aberrant SET Domain, Bifurcated 1 (SETDB1) gene
expression can silence critical tumor suppressor genes
and induce a more aggressive tumor phenotype in HNC
(Bakhtiar et al., 2015; Mochizuki et al., 2018).
Epigenetic regulation is a critical process that regulates noncoding RNA in eukaryotic cells, DNA methylation, covalent-histone modifications, and gene expression
involving noncovalent mechanisms (Dawson et al., 2012).
Epigenetic regulation mechanisms control the genome
function together by changing structural dynamics in
some regions of the chromatin and various processes such
as aging, embryological development, and carcinogenesis
(Sun et al., 2014). The alteration of epigenetic mechanisms
including DNA methylation and histone modification is
reportedly linked to cancer pathogenesis and has begun
to attract the attention of therapeutic researchers in the
development of targeted molecular therapeutic strategies
(Dawson et al., 2012). Moreover, as an important histone
modification, the histone methyltransferases (HMTs),
which belong to the SET-domain protein family, have been
demonstrated to be dysregulated in metabolic pathways
and promote the emergence of a tumorigenic phenotype
(Baylin et al., 2006). SETDB1 (SET Domain, Bifurcated 1,
ESET, KMTLE) as an HMT adds three methyl groups to
the lysine residue (H3K9me3) and silences the expression
of important genes due to the formation of heterochromatin (Dodge et al., 2004). The human SETDB1 (Q9UPS6)
is a 143.1-kDa protein encoded by the localized SETDB1
gene on chromosome 1q21. SETDB1 is essential for embryogenesis (Matsui et al., 2010), the development (Matsui et al., 2016) and inactivation of the X chromosome,
and cellular differentiation (Minkovsky et al., 2014). The
overexpression of SETDB1 has been reported to induce
the modulation of genes associated with various signaling pathways, including those for tumorigenesis and those
that promote cancer invasion and progression (Ceol et al.,
2011; Wong et al., 2016; Huang et al., 2018). The increased

expression of SETDB1 is correlated with HNC progression
in The Cancer Genome Atlas (TCGA) (https://www.cancer.gov). However, the role of SETDB1 in HNC biology has
not yet been clarified.
Therefore, in our study, SETDB1 gene expression in
HNC cell lines was studied at the mRNA and protein levels. In addition, we investigated the effect of its suppression
on the viability, wound-healing capacity, and level of caspase-3 activity of HNC cells by SETDB1 knockdown with
small interference RNA (siRNA) technology.
2. Materials and methods
2.1. Cell culture
Three pairs of primary and metastatic cancer cell lines
were used, and their clinicopathological characteristics
are summarized in Table 1. The cell lines were seeded on
Dulbecco’s modified Eagle’s medium (DMEM) (SigmaAldrich, Germany) along with 10% fetal bovine serum,
1% penicillin-streptomycin, 1% L-glutamine, and 0.01%
Plasmocin. They were cultured in a humidified incubator
with 95% air and 5% CO2 at 37 °C. The movement of cells
and the tracing process were observed using an inverted
microscope (Leica, Germany).
2.2. Quantitative reverse transcription polymerase chain
reaction (qRT‐PCR)
Quantitative reverse transcription polymerase chain
reaction (qRT-PCR) was used to detect the level of
SETDB1 gene expression in the cell lines. A High Pure
RNA Isolation Kit (Roche Diagnostics, USA) was used to
isolate the RNA. For the qRT-PCR, a Transcriptor High
Fidelity cDNA Synthesis Kit (Roche Applied Science,
Germany) was used to synthesize complementary DNA
(cDNA) in a thermal cycler. Briefly, 2 µL of cDNA was
mixed with 18 µL from the SYBR Green qPCR reaction
kit (Roche Applied Science, Germany) for the qRT‐PCR
using primer pairs (Table 2). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) gene expression was used for
normalization of the SETDB1 expression in qRT-PCR
using the comparative CT method (ΔΔCT) (Livak and

Table 1. The characteristics of the HNC cell lines.
Cell lines

Origin
16A Tongue

Primary cell lines (A series)

Sex/age Classification
F/77

T3N0M0/III

42A Laryngeal M/43

T4N3bM0

74A Tongue

M/51

T3N1M0

16B Neck

F/77

T3N0M0/III

Metastatic cell lines (B series) 42B Neck

M/43

T4N3bM0

74B Neck

M/51

T3N1M0

HNC = Head and neck cancer; M = male; F = female; TNM = tumor stage
involvement size, lymph node status, distance of metastases.
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Table 2. The primer sets.
Target gene
SETDB1
GAPDH

Direction Primers
F

5’ TTAACACAGGCCCTGAATTTCT 3’

R

5’ TACCCCTGTGGGTAGACACTCT 3’

F

5’ GAAGGTGAAGGTCGGAGTC 3’

R

5’ GAAGATGGTGATGGGATTTC 3’

SETDB1= SET Domain, Bifurcated 1; GAPDH = glyceraldehyde-3phosphate dehydrogenase; Forward = F; Reverse = R.

Schmittgen, 2001). qRT-PCR was carried as described in
the manufacturer’s protocol (Rotor-Gene Q 5plex HRM
Platform; QIAGEN, Germany) (Sun et al., 2014).
2.3. Western blotting
The SETDB1 protein expression level was assessed by
western blotting. The confluent siRNA SETDB1 and control
cells were washed with 1 mL of Dulbecco’s phosphatebuffered saline (DPBS) at 4 °C three times and lysed in a
radioimmunoprecipitation assay (Thermo Scientific, USA).
Mammalian Protein Extraction Reagent (M-PER; Thermo
Scientific, USA) was used to isolate the total proteins. The
concentrations of these isolated proteins were measured
using the Bradford method. For western blotting, 20 µg of
each protein was used. The proteins were loaded onto SDSPAGE gel and run in ProSieve EX running buffer (Lonza
Bioscience, USA) by electrophoresis. Next, the protein
was transferred to membranes (Lonza Bioscience, USA).
The membranes along with the transferred proteins were
blocked in 5% nonfat milk and incubated with primary
rabbit monoclonal antibody-SETDB1 diluted to 1:1000
(Cell Signaling, USA) and subsequently with secondary
anti-rabbit IgG HRP-linked antibody. β-Actin was used
for normalization. Protein bands were observed with ECL
solution (Bio-Rad, USA) and their relative densities were
assessed with densitometric analysis by using Image Lab
software (Bio-Rad, USA) (Sun et al., 2011; Taylor et al.,
2013; Özdaş, 2018).
2.4. Transient transfection
The UT-SCC 16A and 16B and UTSCC 74A and 74B cells
were seeded in media without antibiotics (1.2 × 105 cells/
well) and treated with siRNA SETDB1 using a transfection
reagent (DharmaFECT-1, GE Healthcare, USA). The
efficiency of the transient transfection in cells treated with
siRNA SETDB1 was assessed by qRT-PCR and western
blotting. The manufacturer’s protocol was followed. After
24 h, the cells were harvested for further analyses.
For transient transfection by siRNA knockdown,
siRNApool technology was used, and all of the siRNAs
were synthesized by Dharmacon (GE Healthcare, USA).
For specific siRNAs SETDB1, for a nonsilencing control

and GAPDH control, the ON-TARGETplus Human
SETDB1 siRNA-SMARTpool and Human Non-TargetingControl Pool and Human GAPDH-Control Pool (GE
Healthcare, USA) were respectively used (Özdaş, 2018).
2.5. Cell viability assay
The MTT assay (3-(4,5-dimethylthiazol-2-thiazolyl)2,5-diphenyl-2H-tetrazolium bromide) (Sigma-Aldrich,
Germany) was used to evaluate the effect of SETDB1 on cell
viability (Na et al., 2016). MTT was dissolved in DPBS (GE
Healthcare, USA). For the MTT assay, after transfection for
24 h, siRNA SETDB1 and the control cells were cultured
with 100 µL of media in 96‐well plates (1–1.2 × 104 cells/
well) under standard conditions. The culture media were
removed following incubation for 24 h, and the cells were
washed with DPBS. Next, the MTT solution was added to
the plate, which was kept for 4 h at 37 °C under standard
incubation conditions. After incubation, the MTT solution
was removed, and the formazan crystals on the plate were
dissolved in 100 µL of dimethyl sulfoxide (Sigma-Aldrich,
Germany). The absorbance at 570 nm was measured using
a spectrophotometer (Shimadzu, UVmini-1240).
2.6. Caspase-3 activity assay
To evaluate SETDB1’s effect on caspase-3 activity, a
caspase-3 activity assay was carried out using a kit (SigmaAldrich, Germany) following the manufacturer’s protocol.
After transfection for 48 h, the siRNA SETDB1 and control
cells were cultured into 96-well plates (1–1.2 × 104 cells/
well) under standard incubation conditions. The caspase
activity was measured at absorbance of 405 nm using a
spectrophotometer (Ko et al., 2014).
2.7. Scratch wound-healing assay
To evaluate SETDB1’s effect on wound closure, a scratch
assay was performed. The siRNA SETDB1 and control cells
were cultured into six‐well plates (1–1.2 × 105 cells/well).
When the monolayer of cells reached confluence, scratch
wounds were created with a 200-µL micropipette tip
and washed with DPBS (GE Healthcare, USA). The cells
were maintained under standard conditions. The wound
area was documented using a Leica inverted microscope
(Frankfurt, Germany) under 10× magnification at 0 h,
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24 h, and 48 h, respectively. The scratch-wound area was
measured using ImageJ software (Wu et al., 2016). The
fractional closure of the wound area was calculated as
the ratio between the relative residual wound area at the
beginning and at the end of the assay.
2.8. Statistical analysis
SPSS 21.0 (IBM Corp., USA) was used for all statistical
analyses, and data are shown as the mean ± standard error
of mean (SEM). The qRT-PCR and caspase-3 activity assay
data were analyzed by Mann–Whitney U test. Student’s
t-test was performed to analyze the other data. P < 0.05
was considered statistically significant.
3. Results
3.1. Overexpression of the SETDB1 gene and the SETDB1
protein in HNC cells
SETDB1 expression was evaluated in primary and
metastatic cell line pairs of HNC by qRT-PCR and western
blotting because dysregulation of SETDB1 is critical for
different signaling pathways and has been suspected to
stimulate cancer phenotypes (Richter et al., 2009; Sun et
al., 2014; Sun et al., 2015). SETDB1 expression was found
to be significantly higher in all metastatic HNC cells than
in their primary counterparts, and its highest expression
level was detected in UT-SCC 74B cells by qRT-PCR (P
< 0.05 for all). In metastatic cell lines, the expression
of SETDB1 compared to the primary cell lines was
significantly increased by ~1.44-fold in UT-SCC 42B/42A,
~1.70-fold in UT-SCC 16B/16A, and ~3.98-fold in UTSCC 74B/74A (respectively, P = 0.019, P = 0.004, and P <
0.001) (Figure 1a).
The expression of the SETDB1 protein was also
assessed by western blotting in HNC cells and was
significantly higher in all metastatic HNC cells than in their
primary counterparts. The strongest expression level was
demonstrated in UT-SCC 74B cells by western blotting,
similar to the qRT-PCR data (Figure 1b). According to
densitometric analysis, the significant increase in the
SETDB1 protein was ~1.15-fold in UT-SCC 42B/42A,
~1.36-fold in UT-SCC 16B/16A, and ~2.39-fold in UTSCC 74B/74A (respectively, P = 0.04, P = 0.03, and P =
0.002) (Figure 1c).
3.2. The efficiency of knockdown of SETDB1 by siRNA
in HNC cell lines
The expression of SETDB1 in HNC cell lines was suppressed
to investigate its functional role in cellular processes using
siRNA technology. The primary and metastatic HNC cell
line pairs of UT-SCC 16 and UT-SCC 74 were treated with
SETDB1 siRNA or nontargeting siRNA as the control. The
efficiency of the knockdown of SETDB1 was studied with
qRT-PCR within 48 h and western blotting within 72 h.
The relative expression of SETDB1 in HNC cell lines
transfected with SETDB1 siRNA compared to control
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siRNA by qRT-PCR was found to be significantly decreased
(P < 0.001 for all) (Figure 2a). Moreover, the expression
of the SETDB1 protein in all HNC cell lines treated with
SETDB1 siRNA was significantly repressed compared to
the control group of siRNA as obtained through western
blotting and its densitometric analysis (P < 0.001 for all)
(Figures 2b and 2c).
3.3. Knockdown of SETDB1 by siRNA decreased cell
viability but induced activation of caspase-3 in HNC cells
To evaluate the effect of SETDB1 knockdown on cell
vitality, the MTT assay was carried out using HNC primary
(UT-SCC 16A, 74A) and metastatic (UT-SCC 16B, 74B)
cell lines treated with SETDB1 siRNA, control siRNA, and
parent cells after knockdown at 48 h. The HNC cell vitality
was measured at 0 h, 24 h, 48 h, and 72 h. The cell viability
of the control siRNA and the parent cells in all cell lines
at each measurement time was similar; no differences
were observed between the groups (P > 0.05). However,
the cell viability in HNC primary (UT-SCC 16A, 74A)
and metastatic (UT-SCC 16B, 74B) cell lines treated with
SETDB1 siRNA in comparison with their control siRNA
and parent cell counterparts was remarkably reduced
in all measurements (P < 0.001 for all). In addition, the
cell viability of HNC metastatic (UT-SCC 16B, 74B) cells
compared with primary (UT-SCC 16A, 74A) cells in all
cell lines treated with SETDB1 siRNA was lower at 24, 48,
and 72 h (P < 0.05 for all) (Figure 3a).
A caspase-3-activity assay was performed to assess the
effect of SETDB1 knockdown on the activation of caspase-3
in HNC primary (UT-SCC 16A, 74A) and metastatic (UTSCC 16B, 74B) cell lines treated with SETDB1 siRNA,
control siRNA, and parent cells. The caspase-3 activity
in the control siRNA and parent cells in all cell lines
was not different in the groups (P > 0.05). The levels of
caspase-3 activity were significantly induced in HNC cell
lines transfected with SETDB1 siRNA compared to control
siRNA and parent cells by ~0.29-fold for primary UT-SCC
16A and by ~0.32-fold for UT-SCC 74A, and by ~0.51fold for metastatic UT-SCC 16B and ~0.67-fold for UTSCC 74B (for all P < 0.001). Moreover, the activation of
caspase-3 rate in HNC metastatic cells (UT-SCC 16B, 74B)
compared with primary cells (UT-SCC 16A, 74A) in all
cell lines treated with SETDB1 siRNA was enhanced (P <
0.05 for all) (Figure 3b).
3.4. Knockdown of SETDB1 by siRNA decreased rate of
wound closure in HNC cells
A scratch wound-healing assay was performed 48 h
after transfection to investigate the effect of SETDB1
knockdown on wound closure in HNC primary (UT-SCC
16A, 74A) and metastatic (UT-SCC 16B, 74B) cell lines
treated with SETDB1 siRNA, control siRNA, parent cells,
and the migrated cells were imaged at 0 h, 24 h, and 48
h. The rate of wound closure in HNC primary (UT-SCC
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Figure 1. SETDB1 expression in HNC cell lines. (a) SETDB1 gene expression was evaluated using qRT-PCR at the mRNA level and with
GAPDH as a housekeeping gene. The relative SETDB1 gene expression increased significantly in the metastatic HNC cell lines (UT-SCC
42B, 16B, 74B) compared to primary defects (UT-SCC 42A, 16A, 74A). GAPDH was used for normalization of qRT-PCR data. The
relative fold change analysis was conducted using the ΔΔCT method. qRT-PCR data expressed the relative fold change and represent the
mean ± SEM for three independent biological replicates. (b) SETDB1 protein expression was evaluated by western blotting. β-Actin was
used for normalization of western blotting data. The expression of the SETDB1 protein was higher in metastatic HNC cell lines (UTSCC 42B, 16B, 74B) compared to primary cell lines (UT-SCC 42A, 16A, 74A). (c) The relative intensities of SETDB1 protein bands were
evaluated densitometrically. Densitometric results showed that there was an overall statistical increase in the amount of SETDB1 protein
for metastatic HNC cell lines compared to primary cell lines. Densitometric analysis was conducted using software. Densitometric
analysis data were expressed as AU and as n-fold over their primary counterparts and represent the mean ± SEM for two independent
biological replicates. *P < 0.05, values were compared with their primary cell lines. UT-SCC = Head and neck squamous cell carcinoma;
SETDB1 = SET Domain, Bifurcated 1; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; ΔΔCT = comparative CT; standard error of
the mean = SEM; AU = arbitrary units.

16A, 74A) and metastatic (UT-SCC 16B, 74B) cells treated
with SETDB1 siRNA in comparison with their parental
cell lines was remarkably decreased at 24 h and 48 h (P
< 0.001 for all). In addition, the rate of wound closure in
HNC metastatic cells (UT-SCC 16B, 74B) compared with

primary cells (UT-SCC 16A, 74A) in all cell lines treated
with SETDB1 siRNA was reduced (P < 0.05 for all) (Figure
4a).
The rate of wound closure in HNC cell lines transfected
with SETDB1 siRNA compared to their parental cells at
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Figure 2. The efficiency of SETDB1 knockdown by siRNA in HNC cell lines. Control siRNA and SETDB1 siRNA were treated in UTSCC 16A, 16B, 74A, and 74B cells. (a) The transfection efficiency was analyzed after 48 h of RT-qPCR. The data indicated that the
expression of the SETDB1 gene was successfully suppressed at the mRNA level in the primary and metastatic HNC cells treated with
SETDB1 siRNA compared to the control siRNA. GAPDH was used for normalization of qRT-PCR data. The relative fold change analysis
was conducted by using the ΔΔCT method. qRT-PCR data were expressed as AU and as n-fold over their control-siRNA and represent
the mean ± SEM for three independent biological replicates. (b) Western blotting analysis showed that the expression of the SETDB1
gene was suppressed at protein level in both the primary and metastatic HNC cells treated with SETDB1 siRNA compared to the
control siRNA. β-Actin was used for normalization of western blotting data. siRNAUT-SCC and ControlUT-SCC indicate the protein levels
of SETDB1 in SETDB1 siRNA and control siRNA cell lines, respectively. (c) The relative intensities of SETDB1 protein bands were
analyzed densitometrically. Densitometric results showed that there was an overall statistical decrease in the amount of SETDB1 protein
in HNC treated with SETDB1 siRNA compared to the control group of siRNA. Densitometric analysis was conducted using software.
Data of the densitometric analysis were expressed as AU and as n-fold over control-siRNA and represent the mean ± SEM for two
independent biological replicates. *P < 0.001, values were compared with their control group of siRNA. HNC = Head and neck cancer;
UT-SCC = head and neck squamous cell carcinoma; SETDB1 = SET Domain, Bifurcated 1; siRNA = small interference RNA; GAPDH =
glyceraldehyde-3-phosphate dehydrogenase; ΔΔCT = comparative CT; standard error of the mean = SEM; AU = arbitrary units.

24 h and 48 h was found to be significantly decreased
by ~0.83-fold and ~0.91-fold for primary UT-SCC 16A,
~0.31-fold and ~0.57-fold for UT-SCC 74A, ~0.35-fold
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and ~0.63-fold for metastatic UT-SCC 16B, and ~0.38-fold
and ~0.68-fold in UT-SCC 74B (P < 0.05 for all) (Figure
4b).

ÖZDAŞ et al. / Turk J Biol

Figure 3. The effect of SETDB1 knockdown by siRNA on cell viability and apoptotic status in HNC cells. (a) The relative cell viability
was evaluated by MTT up to 72 h. Cell viability in primary UT-SCC 16A and 74A, and metastatic UT-SCC 16B and 74B HNC cell lines
by siRNA compared to the control siRNA and parental cell lines was significantly reduced. The metastatic HNC cell lines were more
sensitive to SETDB1 knockdown than the primary cell lines. MTT data are presented as percentage of viable cells and represent the
mean ± SEM for three independent biological replicates. (b) The apoptotic status in HNC cells by caspase-3 activity assay. Apoptotic
activity was induced in the primary UT-SCC 16A and 74A and metastatic UT-SCC 16B and 74B HNC cells treated with SETDB1 siRNA
compared to the control siRNA and parental cell lines. Caspase-3 activity was calculated as OD and represents the mean ± SEM for
three independent biological replicates *P < 0.001, values were compared with their control siRNA and parental cell lines. **P < 0.05,
values were compared with their primary cell lines. HNC = Head and neck cancer; UT-SCC = head and neck squamous cell carcinoma;
SETDB1 = SET Domain, Bifurcated 1; siRNA = small interference RNA; standard error of the mean = SEM; OD = optical density.

4. Discussion
HNC is one of the most common deadly cancers and
therefore presents a growing global public health problem.
HNC’s molecular mechanism has not yet been explained
because no diagnostic follow-up standard algorithms are
available. Alternative strategies for investigating the molecular basis of HNC’s pathogenesis are needed because
current treatment approaches are insufficient and lead to
low quality of life, high toxicity, and the development of
drug resistance. Therefore, the discovery of prognosticdiagnostic biomarkers and potential therapeutic and molecular targets is very urgent (Jemal et al., 2007).
Epigenetic changes, such as excessive histone modifications, have recently been linked to cancer invasion

and progression (Zeng et al., 2010). HMT family members, which were first defined in 2002, allow euchromatic genes to mutate by mediating histone modification
and complexing with proteins, such as SETDB1, CAP-1,
HP1, DNMT3A/B, MBD1, and HDAC1/2 (Fritsch et al.,
2010). SETDB1 proteins are associated with many biological processes, such as Barr bodies and embryogenesis, as
well as gene silence (Matsui et al., 2010; Minkovsky et al.,
2014; Song et al., 2015). Recent reports have revealed the
SETDB1 protein’s functional role in human carcinogenesis
(Sun et al., 2015). Today, SETDB1 is an important research
area because its functional role allows it to act as a therapeutic molecule in cancer treatment (Karanth et al., 2017).
Although some nonspecific inhibitors block the function
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Figure 4. The efficiency of SETDB1 knockdown on wound closure in HNC cells. (a) The cell wound-healing abilities of SETDB1 siRNA
and parental cell lines were evaluated by using scratch wound-healing assay for 48 h. The scratch wound-healing assay demonstrated
that the cell wound-healing ability was decreased in primary UT-SCC 16A and 74A, and metastatic UT-SCC 16B and 74B HNC with
treated SETDB1 siRNA compared to parental cell lines (10× magnification) (scale bar: 500 µm). The green and red lines represent the
edges of the wound at the beginning and at the end of the assay, respectively. (b) The rate of wound closure in HNC cell lines transfected
with SETDB1 siRNA compared to their parental cells at 24 h and 48 h was found to be significantly decreased. The scratch-wound area
was measured using software. The relative scratch-wound area was calculated as the ratio of the wound area’s relative closure at the
beginning and at the end of the assay. The scratch wound-healing assay data are presented as the percentage of the fractional closure of
the wound area and represent the mean ± SEM for three independent biological replicates. *P < 0.001, values were compared with their
parental cell lines. **P < 0.05, values were compared with their primary cell lines. HNC = Head and neck cancer; UT-SCC = head and
neck squamous cell carcinoma; SETDB1 = SET Domain, Bifurcated 1; siRNA = small interference RNA; standard error of the mean =
SEM.

of the SETDB1 protein, there is no specific agent effective
yet, so the study of the role of SETDB1 and its molecular interactions in various cancers can help improve the
therapeutic targeting of SETDB1 in the clinic (RodriguezParedes et al., 2014). In the current study, to investigate the
function of SETDB1 in HNC biology, the gene expression
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in cell lines was suppressed and we analyzed the vitality,
wound-healing ability, and level of caspase-3 activity of
cells.
In our study, we determined SETDB1 gene and protein expression in HNC in vitro. The level of mRNA and
protein expression of the SETDB1 gene in the HNC cell
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lines was higher in each metastatic line compared to its
primary cell line. Studies have reported that the expression
of SETDB1 significantly increases the risk of melanoma
(Ceol et al., 2011), lung cancer (Lindgren et al., 2012), urothelial carcinoma (Wong et al., 2012), glioma (Spyropoulou et al., 2014), ovarian cancer (Hua et al., 2014), prostate
cancer (Sun et al., 2014), breast cancer (Liu et al., 2015),
hepatocellular carcinoma (Wong et al., 2016), colorectal
cancer (Chen et al., 2017), and solid tumors (Huang et al.,
2018). With the increased activity of SETDB1, the excess
trimethylation of various tumor suppressors may block
gene expression, inducing cancer invasion and metastasis.
TCGA data from 44 nontumorous tissues and 522 HNC
tissues were analyzed. The SETDB1 gene expression status was significantly higher for HNC samples (log2PCM
= 5.094) than normal samples (log2PCM = 4.974) (P =
0.0086) (https://www.cancer.gov). Kaplan–Meier analysis also revealed that the increased expression of SETDB1
was significantly correlated with the 5-year survival rate
(50%) of patients with HNSCC (log-rank test, P = 0.009)
(https://www.proteinatlas.org). Considering this evidence,
we believe that SETDB1 may be an attractive biomarker
that demonstrates the prognosis of the disease by acting as
an oncogene of the solid tumor HNC cell lines.
In this study, SETDB1’s upregulation of mRNA and
protein was monitored in HNC cells. To understand the
functional relationship of SETDB1 with HNC and to determine its potential as a therapeutic target, SETDB1 gene
expression was suppressed using siRNA technology. The
gene expression level of SETDB1 was reduced in knockdown cancer cells. It has been observed that the level of
caspase-3 activity, cell viability, and cell wound-healing
ability change in HNC cells after successful transfection
activity.
Sun et al. reported that SETDB1 induces proliferation
and migration of lung carcinogenesis cells by arranging
WNT signaling (Sun et al., 2015). Overexpression of SETDB1 was detected in prostate cancer in clinical and preclinical studies, and the cancer phenotype was suppressed
by siRNA in SETDB1 knockdown cells (Sun et al., 2014).
In colon, lung, and liver cancers, SETDB1 methylated and
silenced T53 in the promoter region, but apoptosis was
stimulated in SETDB1 knockdown cells (Sun et al., 2015;
Wong et al., 2016).
In addition, gliomas (Spyropoulou et al., 2014),
hepatocellular carcinoma (Wong et al., 2016), nasopharyngeal carcinoma (Huang et al., 2018), solid tumors
(Richter et al., 2009), and lung cancer (Rodriguez-Paredes
et al., 2014) have been observed to decrease the viability
and wound-healing ability of SETDB1 knockdown HNC
cells in various cancer types, which is in parallel with studies reporting suppressed SETDB1 expression with siRNA;
P16-INK4A is a tumor suppressor protein that plays a role

in cell cycle regulation (Wang et al., 2003). It has been reported that P16-INK4A in SETDB1 knockdown cells with
increased expression of promoter methylation decreased
active cell viability again (Kostaki et al., 2014). In addition,
Chiba et al. demonstrated that cell viability in a hepatocellular carcinoma control with and without SETDB1 knockdown was similar (Chiba et al., 2015). There was no significant decrease in cell viability in carcinoma cells, but Wu
et al. reported that SETDB1 expression in metastatic lung
cancer cells is low and inhibits cell migration by inhibiting
the polymerization of actin (Wu et al., 2014). According
to Na et al., SETDB1 knockdown increased cell viability in
lung cancer (Na et al., 2016). The effect of SETDB1 knockdown may be different according to the type of cancer and
may play a more critical role in the cancer’s progression.
The scratch wound-healing assay is a classical in vitro
technique to investigate the cell motility that is known
as sheet migration (Rorth, 2012). The epithelial-mesenchymal transition markers, extracellular matrix proteins,
and genes that are associated with rearranging the actin
cytoskeletal are important to provide cell–cell adhesion
and cell–surface adhesion, and furthermore, it is closely
linked with signaling pathways involving cell migration
(Clause and Barker, 2013). Studies reported that SETDB1
may regulate cell motility and migration through the adhesive molecules; however, the relationship among them
is not exactly clear (Wu et al., 2014; Ryu et al., 2019). In
the present study, the knockdown of SETDB1 in HNC cells
reduced the rate of wound-healing. However, SETDB1
knockdown in HNC cells with the underlying mechanisms of cell motility remains to be revealed.
The knockdown of SETDB1 increased the apoptosis
rate in various cancer types (Richter et al., 2009; Spyropoulou et al., 2014; Wong et al., 2016; Huang et al., 2018).
Moreover, Shinoda et al. demonstrated the relationship between SETDB1 and caspase-3 (Shinoda et al., 2016). However, the role of SETDB1 in antiapoptotic mechanisms has
not been completely understood yet, but it may interact
with apoptotic pathways involving caspase-3 (Porter and
Jänicke, 1999). In the current study, SETDB1 knockdown
led to increased levels of caspase-3 activity. Therefore, further studies are needed to assess the effect of SETDB1 on
apoptotic machinery in HNC cells.
Although there are different histological types of HNC,
more than 90% of them are squamous cell carcinoma
(SCC); 27% of these are laryngeal, while 24% are reported
to occur in the oral cavity (Lin et al., 2007). However, most
HNC cell lines are well characterized in our study, and
we know many specific features, such as genetic and epigenetic marker panels, STR profiles, karyotype, radiation
sensitivity, cisplatin sensitivity, status of the P53 mutation,
antigen and integral expression, and activation (Van et al.,
1994; Zhao et al., 2011). Although the cell line models we
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chose reflect the general characteristics of HNC, they each
have genetic phenotypic differences. Although our study is
preclinical and demonstrated the importance of the function of SETDB1 in HNC, it did not explore how it stimulates carcinogenesis through various pathways.
The SETDB1 protein is specifically H3K9me3 and silences the euchromatic genes (Dodge et al., 2004). Furthermore, dysregulation of H3K9me3 through excessive levels
of SETDB1 mRNA expression might silence some of the
critical genes and contribute to tumorigenesis (Karanth et
al., 2017). Several studies showed that SETDB1 interacts
with epigenetic modifiers such as H3K9me3, DNA methyltransferase 3, and CCCTC-binding factor in a direct/indirect way and regulates the epigenetic mechanisms. However, comprehensive insight into the expression and associations of SETDB1 with epigenetic modifiers and its effect
on the epigenome in HNC is still required. For this reason,

further studies applying technological methods, which include well-defined clinical samples, to potential targets of
SETDB1 are needed to clarify the molecular mechanisms
underlying its functional role in HNC cells.
Here, we conducted a preliminary study to explore
the expression of SETDB1 in HNC cell lines. We found
that the overexpression of SETDB1 in HNC metastatic
lines plays a significant role in cancer development. In
addition, our study showed that metastatic HNC cells
are more susceptible to SETDB1 suppression by specific
siRNA, decreased cell vitality and wound-healing ability,
and activation of caspase-3 induced in vitro. We suggest
that targeting SETDB1 that catalyzes histone modification
in HNC treatment will be useful and may be a potentially
diagnostic and prognostic biomarker. Further functional
studies are required to elucidate and verify this potential.
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